Full-Time
HSE & Facilities Specialist
Azenta
1,001-5,000 employees
Automated cold-chain sample management and multiomics
No salary listed
Wotton-under-Edge, UK
In Person
 Facilities Operations (1) |
|---|
Get referred to Azenta
See people who can refer or advise you
- Experience of working with a variety of stakeholders.
- A recognised qualification in health and safety such as IOSH Managing Safely as a minimum.
- Experience of working with data and producing different ways to present data.
- Ability to use the Microsoft Office suite of programs, including Word, Outlook, and Teams.
- The ability to work on a project alone with limited supervision.
- An awareness of training, auditing, compliance, and health and safety, with a desire to progress within this field.
- A qualified health and safety practitioner with a recognised qualification such as NEBOSH or equivalent.
- Provide support to the site to achieve excellent environmental, health, and safety standards across the business through management systems and continuous improvements.
- Assist in the preparation of corporate environmental, health, and safety assessments and management plans.
- Provide support with customer and corporate environmental, social, and governance group requests for information.
- Follow up with line managers to obtain relevant information for incident investigations and near-miss reports.
- Assist with the development of environmental, health, and safety communications and training content as required.
- Assist with internal audits supporting ISO 9001, ISO 13485, and health and safety compliance.
- Keep health and safety notice boards up to date with relevant information.
- Provide updates to site health and safety key performance indicator data, including accident, incident, and near-miss reporting.
- Assist with writing standard operating procedures and provide guidance with risk assessments.
- Assist in preparing health and safety training for new starters.
- Take part in monthly health and safety meetings as part of the health and safety committee.
- Act as the point of contact for facility maintenance issues.
- Act as the initial point of contact for power outages, weather-related hazards or alerts, liquid spills, plumbing issues, and incident clean-up in line with the site business continuity plan.
- Organise and liaise with contractors carrying out repairs to the site.
- Carry out fire drills and help maintain the fire marshal list.
- Support the site leadership team with facility and layout changes.
- Organise first-aid training for staff in line with current legislation.
- Experience working within an ISO 9001 quality assurance system and ISO 13485 quality management system for medical devices.
- Strong written and verbal communication skills.
- Self-motivation in pursuit of environmental, health, and safety objectives.
- Ability to work as part of a larger team.
Azenta provides end-to-end life sciences solutions focused on sample management and genomic services. Its SMS segment offers automated ultra-cold storage, cryogenics, consumables, instruments, and repository services, while the Multiomics segment (GENEWIZ) provides genomic services like sequencing and gene synthesis. The company integrates hardware, consumables, software, and biorepository capabilities to collect, store, and analyze samples across pharma, biotech, academia, and healthcare, with about 55% recurring revenue. Its goal is to speed up drug development, clinical research, and advanced cell therapies by maintaining sample integrity from collection to data analysis.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
1978
Get referred to Azenta
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 fiscal 2026 revenue reached $161.2 million, up 12%, with adjusted EPS beating estimates.
- Azenta completed B Medical Systems sale on July 1, 2026, simplifying the portfolio.
- Custom PCR demand from diagnostic kit makers expands consumables revenue and deepens customer lock-in.
What critics are saying
- John Marotta resigned August 22, 2026, forcing another leadership reset during fragile execution.
- The $35 million B Medical vendor loan faces collectability risk if Thelema's financing collapses.
- May 2026 goodwill impairment, securities probes, and Edwards Vacuum litigation threaten credibility and cash.
What makes Azenta unique
- Azenta's 55% recurring revenue comes from installed sample management workflows and consumables.
- GENEWIZ plus ISO 9001 and 13485 custom PCR manufacturing separates Azenta from catalog sellers.
- UK Biocentre acquisition on March 4, 2026 deepens European biorepository capacity and sample-processing density.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
Custom PCR solutions for diagnostic kit manufacturers. Drawing on its trusted 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation for partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows As molecular diagnostics continue to drive advances in healthcare, manufacturers face growing pressure to deliver high-quality, scalable diagnostic kits while meeting stringent requirements. Not all applications are soluble using off-the-shelf solutions. To support these evolving needs, Azenta Life Sciences offers customised molecular diagnostics solutions that combine proven PCR consumables with bespoke design and manufacturing expertise. Whether adapting existing products or creating entirely custom solutions, the company offers flexible options across PCR plates, sealing materials, sample tracking and automation-compatible consumables to help customers improve reproducibility, simplify manufacturing and accelerate product development. Baskar Anand, Global Product Manager at Azenta, said: "Our customisation capabilities extend from concept through to production." "Customers can specify plate formats, frame and well colours, coatings, surface treatments, seal materials, printing, chemical compatibility and barcode or 2D coding options, alongside contract manufacturing to create solutions that exactly fit your application." He added: "Our customers need more than a catalogue of consumables; they need solutions designed around their manufacturing processes. "By combining high-quality products with flexible customisation, we're helping diagnostic kit manufacturers build workflows that are efficient, reproducible and ready to scale." Azenta has worked with manufacturers to develop customised solutions for applications, including infectious disease diagnostics, supporting automated reagent dispensing, secure heat sealing, sample traceability and compatibility with downstream analytical platforms. All custom products supplied by Azenta are manufactured in ISO9001- and ISO13485-certified facilities, providing the quality systems, consistency and supply reliability required by diagnostic kit manufacturers worldwide. * Companies: * Azenta
Why Azenta (AZTA) stock is down today. What Happened? Shares of life sciences company Azenta AZTA fell 9.1% in the afternoon session after the company announced, in a regulatory filing, that President and CEO John Marotta resigned from his executive roles and board seat, with current director Dr. Martin Madaus appointed as interim President and CEO. Dr. Madaus, who joined the board in 2024 and serves as a Senior Operating Executive at the Carlyle Group, brings extensive executive experience from previous leadership roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America. Azenta confirmed that executive search firm Heidrick & Struggles has been retained to identify a permanent successor. In addition to the management change, the company reaffirmed its fourth-quarter fiscal 2026 revenue guidance but noted that fourth-quarter adjusted EBITDA will be reduced by a one-time consulting expense of approximately $3 million. What Is The Market Telling Us Azenta's shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 7 months ago when the stock dropped 24.6% on the news that it reported mixed fourth-quarter results that failed to impress investors. While the company's revenue of $148.6 million was flat year over year, it did narrowly beat Wall Street's estimates. Similarly, its adjusted earnings per share of $0.14 met expectations. However, the positive notes were overshadowed by a significant miss on profitability. Azenta's adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a key measure of operational profitability, was $12.7 million, falling 29% short of the consensus forecast. The company's cash generation also weakened, with its free cash flow margin declining to 9.9% from 14.9% in the same quarter last year. Overall, the stagnant sales growth and considerable weakness in underlying profitability signaled to investors that the company's financial health was not as strong as hoped, leading to a sharp sell-off. Azenta is up 1.5% since the beginning of the year, but at $33.89 per share, it is still trading 17.4% below its 52-week high of $41.01 from January 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Azenta's shares 5 years ago would now be looking at only $414.94. ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who's building AI, one company is already using it to print money. And nobody's paying attention. AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won't last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
AZENTA announces leadership transition. Aug 24, 2026, 08:00 ET Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company. Dr. Madaus has served in multiple CEO roles in the diagnostics and life science tools industry and joined the Azenta Board in 2024 - making him the ideal individual to lead the Company during this transition. He is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG) and has a proven track record of creating shareholder value in both public and private life science companies. Notably, he has served as Chairman, President and CEO of Millipore Corporation, Chairman and CEO of Ortho-Clinical Diagnostics, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG. The Board has retained leading search firm Heidrick & Struggles, and a search process for a permanent CEO is underway. Additionally, the Company is reaffirming its fourth quarter fiscal 2026 total revenue guidance previously issued on August 4, 2026. The Company now expects fourth quarter fiscal 2026 adjusted EBITDA to be impacted by a one-time approximately $3 million consulting expense that will be recorded in the fourth quarter. Excluding this one-time charge, the Company would be reaffirming adjusted EBITDA as well. Frank E. Casal, Chairman of the Azenta Board, said, "Azenta's focus remains on executing our long-range strategic plan to drive profitable, sustainable value creation. The Board regularly analyzes the performance of our core business units and will continue to evaluate which areas merit targeted reinvestments, while also maintaining a disciplined approach to capital deployment. As discussed on our third quarter earnings call earlier this month, we have seen notable progress in terms of revenue and profitability, and the Board is confident that Martin is the ideal choice to help build on this positive momentum and guide Azenta during this transition period. His track record of successful leadership in our sector speaks for itself, and we believe his deep familiarity with our businesses from his time on the Board will help allow for a seamless transition for our customers, partners, and employees." Dr. Madaus said, "I am pleased to be taking on this role and look forward to leading Azenta as we continue to focus on disciplined execution and advancing key initiatives in support of our strategic plan. I have long admired Azenta as a leader in the space and believe that, with the support of the Company's incredibly talented team, we can accelerate our efforts to meet our commitments and deliver value for shareholders." Mr. Casal continued, "On behalf of the Board, I would like to thank John for his contributions to Azenta." Dr. Martin Madaus Full Biography Dr. Martin Madaus has more than 30 years of leadership experience in diagnostics and life science tools, both as an executive and a board member. He is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG), a global investment firm with $485 billion in assets under management. In addition to the Board of Azenta, he also currently serves as Chair of the Board of Repligen Corporation and as a director at Haemonetics Corporation (NYSE: HAE). He previously served as Chairman and CEO at Ortho-Clinical Diagnostics (now QuidelOrtho Corporation), Chairman, President and CEO of Millipore Corporation, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG (SWX: ROG). He earned a Doctor of Veterinary Medicine Degree from the University of Munich, Germany, and a Ph.D. in Veterinary Medicine from the Veterinary University of Hannover, Germany. "Safe Harbor Statement" under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended Some statements in this release are forward-looking statements made under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's actual financial and business results to differ materially from those expressed or implied by such statements. They are based on the facts and assumptions known to management at the time they are made. Forward looking statements include, but are not limited to, statements regarding the Company's guidance, the Company's long-range plan, the Company's analyses of its core business units and its investments and capital deployment and the Company's expectations with respect to Dr. Madaus' role as Interim President and CEO and his impact on the Company's business, customers, partners, employees and shareholders. Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company's ability to ensure a smooth CEO transition; the Company's ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company's ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; risks relating to the collectability and timely repayment of the $35 million secured vendor loan extended to the buyer in connection with the B Medical Systems divestiture, including the buyer's ability to obtain permanent financing, the sufficiency of the collateral securing the loan, and the potential for an associated charge or impairment; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected. Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com. AZENTA INVESTOR CONTACTS: Yvonne Perron Vice President, Financial Planning & Analysis and Investor Relations [email protected] Maria Isabel Cuartas Manager Investor Relations [email protected] AZENTA MEDIA CONTACT: Joe Germani / Dan Zacchei Longacre Square Partners [email protected] SOURCE Azenta
Azenta Life Sciences' custom PCR solutions for diagnostic kit manufacturers. Published: 18 August 2026 Expanding on its 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation for partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows As molecular diagnostics drive advances in healthcare, manufacturers are under mounting pressure to provide high-quality, scalable diagnostic kits while meeting stringent requirements. Not all applications are soluble using off-the-shelf solutions. Azenta Life Sciences offers customised molecular diagnostic solutions to support these evolving needs. The solutions combine proven PCR consumables with bespoke design and manufacturing expertise. Whether adapting existing products or creating custom solutions, the company provides flexible options across PCR plates, sealing materials, sample tracking, and automation-compatible consumables to help customers enhance reproducibility, simplify manufacturing, and accelerate product development. Baskar Anand, global product manager, Azenta, said, "Its customisation capabilities extend from concept through to production. Customers can specify plate formats, frame and well colours, coatings, surface treatments, seal materials, printing, chemical compatibility, and barcode or 2D coding options, alongside contract manufacturing to create solutions that exactly fit your application. "Our customers need more than a catalogue of consumables - they need solutions designed around their manufacturing processes. By combining high-quality products with flexible customisation, we're helping diagnostic kit manufacturers build workflows that are efficient, reproducible, and ready to scale." Azenta works with manufacturers to develop customised solutions for applications such as infectious disease diagnostics, supporting automated reagent dispensing, secure heat sealing, sample traceability, and compatibility with downstream analytical platforms. Azenta manufactures custom products in ISO 9001- and ISO 13485-certified facilities, providing the quality systems, consistency, and supply reliability that a diagnostic kit manufacturer requires.
Azenta exceeded Wall Street expectations in its second quarter, posting revenue of $161.2 million against estimates of $149.2 million and adjusted earnings per share of $0.16 versus the anticipated $0.10. The company reported 12% year-on-year revenue growth. CEO John Marotta attributed the outperformance to robust growth in biorepositories and consumables segments, alongside improved execution in Multiomics, particularly in Europe and China. Adjusted EBITDA reached $18.46 million, beating analyst estimates of $16.4 million. During the earnings call, analysts focused on sustainability of the North American recovery, order trends, and capital equipment conversion. Marotta noted strong growth in China and Europe but highlighted ongoing challenges in North America's capital equipment market. The company is transitioning from customised to configurable systems whilst maintaining a disciplined approach to capital allocation and mergers and acquisitions.